Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 16/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790650 | 0.90 | HDAC2 (0.65) | HDAC2HDAC1HDAC3 | |
| SCHEMBL3786645 | 0.89 | AAK1 (0.53) | HDAC2HDAC1MAP4K4AAK1CYP17A1 | |
| SCHEMBL2227781 | 0.88 | AAK1 (0.48) | HDAC2HDAC1HDAC3MAP4K4AAK1 | |
| SCHEMBL3791592 | 0.88 | HDAC2 (0.51) | HDAC2HDAC1HDAC3AAK1CYP17A1 | |
| SCHEMBL1646305 | 0.84 | AAK1 (0.47) | HDAC2HDAC1HDAC3MAP4K4AAK1 | |
| SCHEMBL3786879 | 0.82 | HDAC2 (0.48) | HDAC2HDAC1HDAC3AAK1 | |
| SCHEMBL29741562 | 0.82 | HPGD (0.49) | HDAC2HDAC1HDAC3AAK1 | |
| SCHEMBL3407965 | 0.82 | HPGD (0.49) | HDAC2HDAC1HDAC3AAK1 | |
| SCHEMBL12772333 | 0.82 | CYP17A1 (0.53) | HDAC1MAP4K4AAK1CYP17A1 | |
| SCHEMBL20057682 | 0.81 | AAK1 (0.47) | HDAC2HDAC1HDAC3MAP4K4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | HDAC2 549/4885HDAC1 1686/4885HDAC3 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.